For instance, brentuximab vedotin and trastuzumab emtansine can utilize EVs carrying CD30-positive and HER2-positive markers released by tumor cells to target neighboring tumor cells lacking these antigens, leading to tumor regression [93,94,95] (Figure 1). This evidence concerns the gene TNFRSF8 and neoplasm.